KAS
TCRX icon

Kestra Advisory Services’s TScan Therapeutics TCRX Stock Holding History

Kestra Advisory Services’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.3K Hold
62,525
– – ﹤0.01% 3206
2026
Q1 		$63.1K Buy
+62,525
New +$66.8K ﹤0.01% 3054

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Kestra Advisory Services's TCRX Position: Q2 2026 in Review

Kestra Advisory Services held its TScan Therapeutics (TCRX) position steady in Q2 2026 at 62,525 shares worth $61.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3206.

Kestra Advisory Services first reported a position in TCRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $63.1K in Q1 2026. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Kestra Advisory Services held 62,525 shares of TScan Therapeutics worth $61.3K as of Q2 2026.
  • Kestra Advisory Services left its TScan Therapeutics share count unchanged in Q2 2026.
  • TScan Therapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q2 2026, its #3206 holding.
  • Kestra Advisory Services first reported a position in TScan Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Kestra Advisory Services's TScan Therapeutics position peaked at $63.1K in Q1 2026.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.